ClinicalTrials.gg
WithdrawnNCT03608501IDEALLUpdated Jan 14, 2020

A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation

A Phase 2 interventional study of Ixazomib and Thalidomide in Multiple Myeloma, sponsored by Takeda. Withdrawn at 6 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-14.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Business decision (no safety or efficacy concerns)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies testing ixazomib in Multiple Myeloma — 1 open to participants now, 7 under way, none of them phase 3. ixazomib · Multiple Myeloma.

Enrollment
66th of 68
0 · median 48
Started
2019
with 10 others
Phase 2
38 of 68
none open now
Registered
48th of 68
by date
Lead sponsor
10 of 68
Takeda

Among the 68 studies testing ixazomib in Multiple Myeloma, this one is the 66th largest by enrollment, is one of 11 that started in 2019, is one of 38 in phase 2, and was the 48th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 68 studies testing ixazomib in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ixazomib

ixazomib: first FDA approval 2015 (NINLARO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies testing ixazomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine the overall response rate (ORR) during induction therapy with the combination of ixazomib, thalidomide and low-dose dexamethasone in specific time points.

Read the detailed description

The drugs being tested in this study are a combination therapy of ixazomib, thalidomide and low-dose dexamethasone. This combination therapy is being tested to treat people who are newly diagnosed with multiple myeloma and non-eligible to autologous stem cell transplantation (ASCT). This study will assess the ORR during induction therapy in specific timepoints.

The study will enroll approximately 40 participants. All participants will receive:

Ixazomib citrate 4 mg + Thalidomide 100 mg and Dexamethasone 40 mg.

All participants will be asked to take their study medication at approximately the same time each day.

This multi-center trial will be conducted in Brazil. The overall time to participate in this study is approximately 5 years. Participants will make multiple visits to the clinic, and will be contacted by telephone or will make a final visit 30 days after receiving their last dose of drug or resolution of serious adverse event (SAE), whichever occurs later for a follow-up assessment.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clonal bone marrow plasma cells >=10% or -proven bony or extramedullary plasmacytoma and any one or more of the following myeloma defining events:

    • Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically:

      • Hypercalcaemia: serum calcium greater than (>) 1 mg/dL higher than the (ULN) or >11 mg/dL;
      • Renal insufficiency: \<40 milliliter (mL) per minute (as per validated equations) or serum creatinine >2 mg/dL;
      • Anemia: value of >20 gram per liter (g/L) below the lower limit of normal, or a haemoglobin value \<100 g/L;
      • Bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron emission tomography (PET)-CT.
    • Any one or more of the following biomarkers of :

      • Clonal bone marrow plasma cell percentage >=60%.
      • Involved: uninvolved serum free light chain ratio >=100.
      • Greater than (>) 1 focal lesions on magnetic resonance imaging (MRI) studies. Note: clonality should be established by showing kappa to lambda ratio (κ/λ)-light-chain restriction on flow cytometry, immunohistochemistry, or immunofluorescence. Bone marrow plasma cell percentage should preferably be estimated from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be used.
  2. Ineligibility to transplantation, as per investigator's discretion, regardless of age (the reason for such ineligibility should be recorded on the electronic case report form [eCRF]).
  3. (ECOG) performance status of 0 to 2.
  4. Ability to take concurrent aspirin daily (or enoxaparin subcutaneously daily), per published standard or institutional standard of care, as prophylactic anticoagulation.
  5. Note: For participants with prior history of deep vein thrombosis (DVT), low molecular weight heparin (LMWH) is mandatory.
  6. (LVEF) >=50%.
  7. Clinical laboratory values as specified below within 7 days before the first dose of study drug:

    • (ANC) >=1,500 per cubic millimeter (/mm\^3), unless related to bone marrow infiltration by malignant plasma cells.
    • Hemoglobin >=8.0 g/dL
    • count >=75,000/mm\^3, unless related to bone marrow infiltration by malignant plasma cells (platelet transfusions to help participants meet eligibility criteria are not allowed).
    • (AST) and alanine aminotransferase (AST) less than or equal to (\<=) 1.5 times the institutional ULN.
    • \<=1.5 mg/dL (or \<=2.5 mg/dL in case of Gilbert-Meulengracht syndrome).
    • >=30 milliliter per minute per (mL/min/) 1.73 square meter (m\^2) according to the Modification of Diet in Renal Disease (MDRD) study abbreviated formula. If not on target, this evaluation may be repeated once after at least 24 hours.
    • (PT) or activated partial thromboplastin time (aPTT) within normal limits.

Exclusion criteria

Exclusion Criteria:

  1. Presence of non-secretory or oligo-secretory myeloma, smoldering MM, monoclonal gammopathy of undetermined significance, plasma-cell leukemia, Waldenstrom's macroglobulinemia, primary amyloidosis, or polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome.
  2. Central nervous system involvement by MM.
  3. Prior radiation therapy involving an estimated >=25% of the hematopoietically active bone marrow. Radiotherapy should not be given within 14 days before enrollment. In case of palliative radiotherapy for pain control and if the involved field is small, 7 days will be considered a sufficient interval between the radiation treatment and administration of the study drugs.
  4. Treatment with any products within 1 (one) year before the first dose of the study drug regimen.
  5. Presence of peripheral neuropathy of grade 1 with pain or grade 2 or higher.
  6. Previous or concurrent history of other than MM except for curatively treated cervical carcinoma in situ, non-melanoma skin cancer, superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria]), or localized prostate cancer.
  7. With evidence or history of bleeding diathesis. Any hemorrhage or bleeding event >= (CTCAE) Grade 3 within 4 weeks of start of study medication.
  8. Major surgery within 14 days before randomization.
  9. Non-healing wound or ulcer.
  10. Seizure disorder requiring medication.
  11. Systemic treatment with strong cytochrome P-450 3A () inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort from Day-14 of cycle 1 until the safety follow-up.
  12. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 3 months before the start of study medication.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Ixazomib 4 mg + Thalidomide 100 mg + Dexamethasone 40 mg

    Ixazomib 4 milligram (mg), capsule, orally, once on Days 1, 8 and 15 along with thalidomide 100 mg, tablet, orally, once daily and dexamethasone 40 mg, tablet, orally, once on Days 1, 8, 15 and 22 in a 28-day treatment cycle for up to 9 cycles or until withdrawal from the study in the treatment phase. Participants who complete treatment phase will be eligible to continue on to the maintenance phase of the study to receive ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of a 28-day treatment cycle for up to 24 months or until withdrawal from the study.

    Drug: Ixazomib · Drug: Thalidomide · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. ORR During Induction

    ORR is the percentage of participants with presence of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). ORR assessment will be based on International Myeloma Working Group (IMWG) response criteria.

    Time frame: Upon ORR assessment during specific timepoints for all participants completing or withdrawn prematurely from the induction phase (Baseline up to approximately 9 month [Cycle 9])

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS is the time elapsed between treatment initiation and first PD documentation or death from any cause, where PD is assessed by IMWG response criteria.

    Time frame: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 2 years])

  2. ORR During Maintenance

    ORR is the percentage of participants with presence of sCR, CR, VGPR or PR. ORR assessment will be based on IMWG response criteria.

    Time frame: Upon ORR assessment during specific time points for all participants completing or withdrawn prematurely from maintenance phase (Baseline up to approximately 2 years)

  3. Overall Survival (OS)

    OS is defined as the time elapsed between treatment initiation and death from any cause.

    Time frame: Upon study termination (Baseline up to approximately 5 years)

  4. Time to Response During Induction

    Time to response is the time elapsed between treatment initiation and the first documentation of sCR, VGPR or PR according to the IMWG response criteria.

    Time frame: End of induction phase (Baseline up to approximately 9 months [Cycle 9])

07

Study locations

6 sites
  • CEHON Centro de Hematologia e Oncologia da Bahia
    Salvador, BA 40110-090, Brazil
  • Instituto COI de Educacao e Pesquisa
    Rio de Janeiro, RJ 22793-080, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, RS 90035-003, Brazil
  • Universidade Estadual de Campinas UNICAMP - HEMOCENTRO
    Campinas, SP 13083-878, Brazil
  • Clinica Medica Sao Germano S/S Ltda.
    Sao Paulo, SP 04537-080, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da USP
    Sao Paulo, SP 05403-010, Brazil
08

References and documents

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2019; primary completion for Jun 2021, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2018
First posted
Aug 1, 2018
StartEst.
Sep 30, 2019
Primary completionEst.
Jun 30, 2021
CompletionEst.
May 31, 2023
Last update
Jan 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03608501
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Aug 1, 2018
Start date
Sep 30, 2019 (estimated)
Primary completion
Jun 30, 2021 (estimated)
Completion
May 31, 2023 (estimated)
Last update
Jan 14, 2020

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ixazomib · Thalidomide · Dexamethasone

Start the discussion